Murakoshi Maki, Kamei Nozomu, Suzuki Yusuke, Kubota Mitsunobu, Sanuki Michiyoshi, Tashiro Hirotaka, Iwasawa Takumi, Kato Kazunori, Tanaka Marenao, Furuhashi Masato, Gohda Tomohito
Department of Nephrology, Juntendo University Faculty of Medicine, Tokyo, Japan.
Department of Endocrinology and Metabolism, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan; Institute for Clinical Research, National Hospital Organization, Kure Medical Center and Chugoku Cancer Center, Hiroshima, Japan.
Diabetes Res Clin Pract. 2023 Dec;206:111017. doi: 10.1016/j.diabres.2023.111017. Epub 2023 Nov 14.
Tumor necrosis factor (TNF) receptors (TNFRs: TNFR1 and, TNFR2) are reportedly associated with chronic kidney disease (CKD) progression chiefly in Caucasian patients with diabetes. We assessed the prognostic value of TNF-related biomarkers for CKD progression in Japanese patients with diabetes.
We estimated TNF-related biomarkers using an enzyme-linked immunosorbent assay in 640 patients with diabetes. Cox proportional hazards analysis was performed to estimate hazard ratios (HRs) per one standard deviation (SD) increase in a log-transformed biomarker. The kidney and the composite outcome were defined as a 30% reduction in estimated glomerular filtration rate (eGFR) from baseline, and kidney outcome plus death before kidney outcome, respectively.
During the median follow-up of 5.4 years, 75 (11.7%) patients reached the kidney outcome and 37 (5.8%) died before reaching the kidney outcome. Each SD increase in baseline circulating TNFR1, TNFR2, and ephrin type-A receptor 2 (EphA2) was associated with a higher risk of the kidney outcome independently from baseline eGFR and urine albumin-to-creatinine ratio. However, circulating osteoprotegerin was associated with the composite outcome only.
Elevated TNFR1, TNFR2, and EphA2 were associated with both kidney and composite outcomes in Japanese patients with diabetes.
据报道,肿瘤坏死因子(TNF)受体(TNFRs:TNFR1和TNFR2)主要与患有糖尿病的白种人慢性肾脏病(CKD)进展相关。我们评估了TNF相关生物标志物对日本糖尿病患者CKD进展的预后价值。
我们使用酶联免疫吸附测定法对640例糖尿病患者的TNF相关生物标志物进行了评估。进行Cox比例风险分析以估计对数转换后的生物标志物每增加一个标准差(SD)的风险比(HRs)。肾脏结局和综合结局分别定义为估计肾小球滤过率(eGFR)较基线降低30%,以及肾脏结局加肾脏结局前死亡。
在中位随访5.4年期间,75例(11.7%)患者达到肾脏结局,37例(5.8%)在达到肾脏结局前死亡。基线循环TNFR1、TNFR2和 Ephrin A型受体2(EphA2)每增加一个SD,独立于基线eGFR和尿白蛋白与肌酐比值,均与更高的肾脏结局风险相关。然而循环骨保护素仅与综合结局相关。
在日本糖尿病患者中,TNFR1、TNFR2和 EphA2升高与肾脏结局和综合结局均相关。